Scholarlink

<p>Epithelial ovarian cancer (EOC) is the most frequent histological subtype of ovarian cancer, accounting for 95% of ovarian cancer. Radiologists are familiar with the imaging appearances of high-grade serous ovarian cancer (HGSOC) that accounts for about 70% of EOC. Low grade serous ovarian cancer (LGSOC) represents 2–5% of ovarian carcinomas and 5–10% of serous ovarian carcinoma. Historically, it was thought that LGSOC and HGSOC were a continuum. It is now clear that these are two completely separate entities. They have different molecular biology and clinical course. As a result of the low prevalence of LGSOC, there is limited data on its imaging findings. In this paper, we illustrate the pathology, molecular biology and treatment options of LGSOC. We present imaging appearances of LGSOC of primary tumor and metastasis in a cohort of 33 patients with pathologically-proven LGSOC. We also elucidate the differences between LGSOC and HGSOC. Since LGSOC often arise from serous borderline ovarian tumors (SBOT), we describe the imaging appearances of SBOT and highlight the differences between these two entities.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serous borderline ovarian tumor and low-grade serous ovarian cancer

  • 期刊论文

  • 发表日期：

    2025年8月1日

查看全文
  • Kumaresan Sandrasegaran,
  • Abhijit Das,
  • Amar Shah,
  • Mark Sugi,
  • Ayana Jain,
  • Nelly Tan,
  • Kristina Butler,
  • Motoyo Yano,
  • Christine Menias

摘要

Epithelial ovarian cancer (EOC) is the most frequent histological subtype of ovarian cancer, accounting for 95% of ovarian cancer. Radiologists are familiar with the imaging appearances of high-grade serous ovarian cancer (HGSOC) that accounts for about 70% of EOC. Low grade serous ovarian cancer (LGSOC) represents 2–5% of ovarian carcinomas and 5–10% of serous ovarian carcinoma. Historically, it was thought that LGSOC and HGSOC were a continuum. It is now clear that these are two completely separate entities. They have different molecular biology and clinical course. As a result of the low prevalence of LGSOC, there is limited data on its imaging findings. In this paper, we illustrate the pathology, molecular biology and treatment options of LGSOC. We present imaging appearances of LGSOC of primary tumor and metastasis in a cohort of 33 patients with pathologically-proven LGSOC. We also elucidate the differences between LGSOC and HGSOC. Since LGSOC often arise from serous borderline ovarian tumors (SBOT), we describe the imaging appearances of SBOT and highlight the differences between these two entities.